The consensus price target hints at a 43.7% upside potential for Recursion Pharmaceuticals (RXRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
For the next stage of the AI era, companies with purposeful, practical, and highly targeted solutions stand to benefit the most.
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.